High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACSI

 

 Buy Article Permissions and Reprints

Summary

Despite dual antiplatelet therapy (DAPT), one-year event rates after acute coronary syndrome (ACS) vary from 9–12%. The development of novel oral anticoagulants (NOAC) without a need for monitoring has initiated renewed interest for prolonged adjunctive anticoagulation. Importantly, the cornerstone of treatment after ACS consists of long-term DAPT. In that context, the NOACs have only been tested as adjunctive therapy. Of all new agents, only rivaroxaban –in a substantially lower dose than used for atrial fibrillation– has been demonstrated to improve outcome, albeit at the cost of bleeding. In selected cases, adjunctive therapy with dose-adjusted vitamin-K antagonists (international normalized ratio [INR] 2.0–3.0) can be considered as well. These two strategies of prolonged anticoagulation can be considered in case of ‘high platelet reactivity’, i.e. in patients at high risk of recurrent thrombotic events despite DAPT. Both during admission and after discharge for ACS, the use of NOACs in doses indicated for atrial fibrillation is strictly contra-indicated in patients on DAPT. In case of post-discharge anticoagulation therapy for atrial fibrillation, patients should preferably receive vitamin-K antagonists (INR 2.0–3.0), with discontinuation of one antiplatelet agent as soon as clinically justifiable. Importantly, the impact of prolonged anticoagulation (low-dose rivaroxaban, vitamin-K antagonists) as adjunctive to DAPT after ACS has not been addressed with the most potent antiplatelet agents (prasugrel, ticagrelor) and merits further study. Despite the potential indication of prolonged oral anticoagulation as adjunctive treatment, it remains to be established whether anticoagulation therapy could also be an alternative for either aspirin or thienopyridine treatment in selected ACS patients on DAPT.

• References

• 1 AntiThrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009; 373: 1849-1860.
  PubMedGoogle Scholar
• 2 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
  CrossrefPubMedGoogle Scholar
• 3 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
  CrossrefPubMedGoogle Scholar
• 4 Wallentin L, Becker RC, Bidai A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
  CrossrefPubMedGoogle Scholar
• 5 Roe MT, Armstrong PW, Fox KAA. et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularisation. N Engl J Med 2012; 367: 1297-1309.
  CrossrefPubMedGoogle Scholar
• 6 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
  CrossrefPubMedGoogle Scholar
• 7 Steg G, James SK, Atar D. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619.
  CrossrefPubMedGoogle Scholar
• 8 Palmerini T, Dangas G, Mehran R. et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ Cardiovasc Interv 2011; 04: 577-584.
  CrossrefPubMedGoogle Scholar
• 9 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
  CrossrefPubMedGoogle Scholar
• 10 Dangas GD, Claessen BE, Mehran R. et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: Results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularisation and Stents in Acute Myocardial Infarction) Trial. JACC 2012; 59: 1752-1759.
  CrossrefPubMedGoogle Scholar
• 11 Price MJ, Berger PB, Teirstein PS. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention : the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
  CrossrefPubMedGoogle Scholar
• 12 Sibbing D, Byrne RA, Bernlochner I. et al. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Collet JP, Cuisset T, Rangé G. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
  CrossrefPubMedGoogle Scholar
• 14 Furie B, Furie BC. Mechanism of thrombus formation. N Engl J Med 2008; 359: 938-949.
  CrossrefPubMedGoogle Scholar
• 15 Oler A, Whooley MA, Oler J. et al. Adding heparin to aspirin reduces the incidence of myocardial infarction, death in patients with unstable angina A meta-analysis. J Am Med Assoc 1996; 276: 811-815.
  CrossrefPubMedGoogle Scholar
• 16 Petersen JL, Mahaffey KW, Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes, a systematic overview. J Am Med Assoc 2004; 292: 89-96.
  PubMedGoogle Scholar
• 17 De Luca G, Marino P. Adjunctive benefits from low-molecular weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis A meta-analysis of the randomized trials. Am Heart J 2007; 154: 1085. e1-6
  PubMedGoogle Scholar
• 18 Yusuf S, Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
  CrossrefPubMedGoogle Scholar
• 19 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1930.
  CrossrefPubMedGoogle Scholar
• 20 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
  CrossrefPubMedGoogle Scholar
• 21 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
  CrossrefPubMedGoogle Scholar
• 22 Brouwer MA, Verheugt FWA. Oral anticoagulation for acute coronary syndromes. Circulation 2002; 105: 1270-1274.
  CrossrefPubMedGoogle Scholar
• 23 Hsia J, Hamilton WP, Kleiman N. et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437.
  CrossrefPubMedGoogle Scholar
• 24 Williams MJA, Morison IM, Parker JH. et al. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30: 364-369.
  CrossrefPubMedGoogle Scholar
• 25 Brouwer MA, van den Bergh PJ, Aengevaeren WR. et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 trial. Circulation 2002; 106: 659-665.
  CrossrefPubMedGoogle Scholar
• 26 Brouwer MA, Clappers N, Verheugt FWA. Adjunctive treatment in patients treated with thrombolytic therapy. Heart 2004; 90: 581-588.
  CrossrefPubMedGoogle Scholar
• 27 Ross AM, Molhoek P, Lundergan C. et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HART II). Circulation 2001; 104: 648-652.
  CrossrefPubMedGoogle Scholar
• 28 Wijns W, Kohl P, Danchin N. et al. Guidelines on myocardial revascularisation: the Task Force on myocardial revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
  CrossrefPubMedGoogle Scholar
• 29 White H. Hirulog, Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-1863.
  CrossrefPubMedGoogle Scholar
• 30 Wallentin L, Wilcox RG, Weaver WD. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 789-797.
  CrossrefPubMedGoogle Scholar
• 31 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med 2011; 365: 883-891.
  CrossrefPubMedGoogle Scholar
• 32 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with AF. N Engl J Med 2011; 365: 981-992.
  CrossrefPubMedGoogle Scholar
• 33 Alexander JH, Lopes RD, James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
  CrossrefPubMedGoogle Scholar
• 34 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
  CrossrefPubMedGoogle Scholar
• 35 Oldgren J, Budaj A, Granger CB, Dabigatran vs. et al. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789.
  CrossrefPubMedGoogle Scholar
• 36 Andreotti F, Testa L, Biondi-Zoccai GGL. et al. Aspirin plus warfarin compared to aspirin alone after coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006; 27: 519-526.
  CrossrefPubMedGoogle Scholar
• 37 en Berg JM, Kelder JC, Suttorp MJ. et al. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000; 102: 386-391.
  CrossrefPubMedGoogle Scholar
• 38 Testa L, Zoccai GB, Porto I. et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007; 99: 1637-1642.
  CrossrefPubMedGoogle Scholar
• 39 van Geest-Daalderop JHH, Hutten BA, Sturk A. et al. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J Thromb Thrombolysis 2003; 15: 197-203.
  CrossrefPubMedGoogle Scholar
• 40 Cosmi B, Rubboli A, Castelvetri C. et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001; 04: CD002133.
  PubMedGoogle Scholar
• 41 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
  CrossrefPubMedGoogle Scholar
• 42 Granger CB, Goldberg RJ, Dabbous O. et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-2353.
  CrossrefPubMedGoogle Scholar
• 43 Subherwal S, Bach RG, Chen AY. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009; 119: 1873-1882.
  CrossrefPubMedGoogle Scholar
• 44 Steg PG, Huber K, Andreotti F. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
  CrossrefPubMedGoogle Scholar
• 45 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
  CrossrefPubMedGoogle Scholar
• 46 de Araujo Goncalves P, Ferreira J, Aguiar C. et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularisation in NSTE-ACS. Eur Heart J 2005; 26: 865-872.
  CrossrefPubMedGoogle Scholar
• 47 Flather MD, Weitz JI, Yusuf S. et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. Eur Heart J.. 2000; 21: 1473-1481.
  PubMedGoogle Scholar
• 48 Testa L, Zoccai GB, Porto I. et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007; 99: 1637-1642.
  CrossrefPubMedGoogle Scholar
• 49 De Wilde W, Oirbans T, Verheugt F. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label randomised, controlled trial. Lancet. 2013 epub ahead of print
  PubMedGoogle Scholar
• 50 APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischaemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
  CrossrefPubMedGoogle Scholar
• 51 Mega JL, Braunwald E, Mohanavelu S. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.
  CrossrefPubMedGoogle Scholar
• 52 Steg G, Mehta SR, Jukema JW. et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32: 2541-2554.
  CrossrefPubMedGoogle Scholar
• 53 Mega JL, Braunwald E, Murphy SA. et al. Rivaroxaban in patients with ST-elevation myocardial infarction: Results from ATLAS ACS 2-TIMI 51. 2012. Presented at the European Society of Cardiology Annual Congress, Munich; Germany: August 25-29. Abstract session 710007-710008
  Google Scholar
• 54 Lamberts M, Olesen JB, Ruwald MH. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in AF patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation.. 2012 epub ahead of print
  PubMedGoogle Scholar
• 55 Sorensen R, Hansen ML, Abildstrom SZ. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
  CrossrefPubMedGoogle Scholar
• 56 Gao F, Zhou YJ, Wang ZJ. et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol 2010; 148: 96-101.
  PubMedGoogle Scholar
• 57 De Wilde W, ten Berg J. et al. Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 2009; 158: 713-718.
  CrossrefPubMedGoogle Scholar
• 58 Lip GYH, Huber K, Andreotti F. et al. Management of antithrombotic therapy in AF patients presenting with acute coronary syndrome and/or undergoing percutaneous intervention/stenting A consensus document of the European Society of Cardiology working group on thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010; 103: 13-28.
  Article in Thieme ConnectPubMedGoogle Scholar
• 59 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.
  CrossrefPubMedGoogle Scholar